API Osimertinib

Osimertinib More Info

1. Overview

Osimertinib (AZD9291) is a third-generation, oral, irreversible EGFR tyrosine kinase inhibitor. It was specifically designed to overcome resistance mechanisms associated with earlier EGFR inhibitors, particularly the T790M mutation, which is a common cause of treatment failure in EGFR-mutated non-small cell lung cancer (NSCLC) patients. In addition to targeting EGFR, osimertinib also exhibits activity against HER2 and other members of the ErbB family.

2. Mechanism of Action

Osimertinib works by irreversibly binding to the ATP-binding site of the EGFR kinase domain, specifically targeting:

EGFR sensitizing mutations (e.g., exon 19 deletions, L858R).

EGFR T790M resistance mutation, which is the most common mutation that leads to resistance against first- and second-generation EGFR TKIs.

This irreversible binding blocks downstream signaling pathways crucial for tumor cell proliferation and survival, including the PI3K-AKT and RAS-RAF-MEK-ERK pathways. The drug’s selectivity for mutant EGFR over wild-type EGFR contributes to a more favorable safety profile compared to earlier-generation TKIs.

3. Approved Indications (as of 2026)

Osimertinib has received multiple approvals for the treatment of EGFR-mutated NSCLC across different disease stages and treatment settings:

First-Line Treatment: For patients with metastatic EGFR-mutated NSCLC (exon 19 deletions or L858R) who have not received prior EGFR TKI therapy.

Second-Line Treatment: For patients with metastatic EGFR T790M-positive NSCLC who have progressed on prior EGFR TKI therapy.

Adjuvant Therapy: For patients with resected EGFR-mutated NSCLC following complete tumor resection, to reduce the risk of recurrence.

Combination Therapy: Recently approved for frontline use in combination with chemotherapy for advanced EGFR-mutant NSCLC, based on the FLAURA2 trial data.

4. Dosage and Administration

Standard Dose: The recommended dose is 80 mg orally once daily, taken with or without food.

Dose Adjustments: In cases of severe toxicity, the dose can be reduced to 40 mg once daily. However, dose adjustments are generally not required for patients with mild to moderate renal or hepatic impairment.

Special Populations: For patients with severe renal impairment, exposure may increase, but dose adjustments are typically not necessary unless toxicity occurs.

5. Pharmacokinetics

Absorption: Osimertinib has good oral bioavailability, and food does not significantly affect its absorption.

Metabolism: It is primarily metabolized by CYP3A4, with active metabolites (AZ7550 and AZ5104) contributing to its pharmacologic activity.

Elimination: The drug has a relatively long half-life, supporting once-daily dosing, and is excreted primarily via feces.

6. Safety Profile and Contraindications

Common Adverse Events: Diarrhea, rash, dry skin, and nail changes are among the most frequently reported side effects.

Serious Risks: Include interstitial lung disease (ILD), QT interval prolongation, and cardiomyopathy. Patients should be monitored for respiratory symptoms and cardiac function.

Contraindications: Known hypersensitivity to osimertinib or any of its excipients. Caution is advised when co-administered with strong CYP3A4 inducers (e.g., rifampin) as they may reduce drug exposure.

7. Regulatory and Clinical Evidence

Regulatory Status: First approved by the FDA in 2015, with subsequent expansions in indication, including adjuvant therapy and combination regimens in 2024 and 2025.

Clinical Efficacy: Pivotal trials (AURA and FLAURA) demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) compared to standard chemotherapy or first-generation EGFR TKIs. In T790M-positive patients, objective response rates (ORR) have been reported as high as 61%.

Real-World Data: Recent meta-analyses and real-world studies confirm the drug’s high efficacy at the standard 80 mg dose, with a favorable benefit-risk profile, especially in the frontline setting.

Conclusion

Osimertinib represents a cornerstone in the management of EGFR-mutated NSCLC, offering a potent, targeted approach that addresses both primary oncogenic drivers and common resistance mechanisms, thereby improving outcomes across various stages of lung cancer treatment.